FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306173610> ?p ?o ?g. }

• W4306173610 endingPage "142" @default.
• W4306173610 startingPage "120" @default.
• W4306173610 abstract "As the mitogen-activated protein kinase (MAPK) signalling pathway is activated in many paediatric cancers, it is an important therapeutic target. Currently, a range of targeted MAPK pathway inhibitors are being developed in adults. However, MAPK signals through many cascades and feedback loops and perturbing the MAPK pathway may have substantial influence on other pathways as well as normal development. In view of these issues, the ninth Paediatric Strategy Forum focused on MAPK inhibitors. Development of MAPK pathway inhibitors to date has been predominantly driven by adult indications such as malignant melanoma. However, these inhibitors may also target unmet needs in paediatric low-grade gliomas, high-grade gliomas, Langerhans cell histiocytosis, juvenile myelomonocytic leukaemia and several other paediatric conditions. Although MAPK inhibitors have demonstrated activity in paediatric cancer, the response rates and duration of responses needs improvement and better documentation. The rapid development and evaluation of combination approaches, based on a deep understanding of biology, is required to optimise responses and to avoid paradoxical tumour growth and other unintended consequences including severe toxicity. Better inhibitors with higher central nervous systempenetration for primary brain tumours and cancers with a propensity for central nervous system metastases need to be studied to determine if they are more effective than agents currently being used, and the optimum duration of therapy with MAPK inhibition needs to be determined. Systematic and coordinated clinical investigations to inform future treatment strategies with MAPK inhibitors, rather than use outside of clinical trials, are needed to fully assess the risks and benefits of these single agents and combination strategies in both front-line and in the refractory/relapse settings. Platform trials could address the investigation of multiple similar products and combinations. Accelerating the introduction of MAPK inhibitors into front-line paediatric studies is a priority, as is ensuring that these studies generate data appropriate for scientific and regulatory purposes. Early discussions with regulators are crucial, particularly if external controls are considered as randomised control trials in small patient populations can be challenging. Functional end-points specific to the populations in which they are studied, such as visual acuity, motor and neuro psychological function are important, as these outcomes are often more reflective of benefit for lower grade tumours (such as paediatric low-grade glioma and plexiform neurofibroma) and should be included in initial study designs for paediatric low-grade glioma. Early prospective discussions and agreements with regulators are necessary. Long-term follow-up of patients receiving MAPK inhibitors is crucial in view of their prolonged administration and the important involvement of this pathway in normal development. Further rational development, with a detailed understanding of biology of this class of products, is crucial to ensure they provide optimal benefit while minimising toxicity to children and adolescents with cancer." @default.
• W4306173610 created "2022-10-14" @default.
• W4306173610 creator A5002191021 @default.
• W4306173610 creator A5002952095 @default.
• W4306173610 creator A5006499960 @default.
• W4306173610 creator A5008077943 @default.
• W4306173610 creator A5009057245 @default.
• W4306173610 creator A5013529173 @default.
• W4306173610 creator A5015176786 @default.
• W4306173610 creator A5017416578 @default.
• W4306173610 creator A5018886099 @default.
• W4306173610 creator A5019914745 @default.
• W4306173610 creator A5025607486 @default.
• W4306173610 creator A5028407091 @default.
• W4306173610 creator A5030199435 @default.
• W4306173610 creator A5033219974 @default.
• W4306173610 creator A5037169725 @default.
• W4306173610 creator A5041362225 @default.
• W4306173610 creator A5042719910 @default.
• W4306173610 creator A5045245802 @default.
• W4306173610 creator A5046880941 @default.
• W4306173610 creator A5046943976 @default.
• W4306173610 creator A5049106961 @default.
• W4306173610 creator A5050571054 @default.
• W4306173610 creator A5050738935 @default.
• W4306173610 creator A5052706160 @default.
• W4306173610 creator A5054535845 @default.
• W4306173610 creator A5062088729 @default.
• W4306173610 creator A5062735715 @default.
• W4306173610 creator A5066977204 @default.
• W4306173610 creator A5067202962 @default.
• W4306173610 creator A5080060138 @default.
• W4306173610 creator A5083758349 @default.
• W4306173610 creator A5083808934 @default.
• W4306173610 creator A5085484464 @default.
• W4306173610 creator A5085626192 @default.
• W4306173610 creator A5085820190 @default.
• W4306173610 creator A5086018137 @default.
• W4306173610 creator A5086555565 @default.
• W4306173610 creator A5088126403 @default.
• W4306173610 date "2022-12-01" @default.
• W4306173610 modified "2023-09-29" @default.
• W4306173610 title "Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors" @default.
• W4306173610 cites W1968174927 @default.
• W4306173610 cites W1969522518 @default.
• W4306173610 cites W1970654034 @default.
• W4306173610 cites W1980754306 @default.
• W4306173610 cites W2009347177 @default.
• W4306173610 cites W2018759485 @default.
• W4306173610 cites W2022831509 @default.
• W4306173610 cites W2028785929 @default.
• W4306173610 cites W2035346960 @default.
• W4306173610 cites W2037838528 @default.
• W4306173610 cites W2048765718 @default.
• W4306173610 cites W2055388753 @default.
• W4306173610 cites W2055389755 @default.
• W4306173610 cites W2078626081 @default.
• W4306173610 cites W2097946365 @default.
• W4306173610 cites W2127736279 @default.
• W4306173610 cites W2129907014 @default.
• W4306173610 cites W2137224782 @default.
• W4306173610 cites W2162079601 @default.
• W4306173610 cites W2169438753 @default.
• W4306173610 cites W2171512544 @default.
• W4306173610 cites W2213548494 @default.
• W4306173610 cites W2264170040 @default.
• W4306173610 cites W2567378356 @default.
• W4306173610 cites W2587847258 @default.
• W4306173610 cites W2652551831 @default.
• W4306173610 cites W2732767128 @default.
• W4306173610 cites W2740873526 @default.
• W4306173610 cites W2751187578 @default.
• W4306173610 cites W2756862815 @default.
• W4306173610 cites W2789869568 @default.
• W4306173610 cites W2789924919 @default.
• W4306173610 cites W2800596816 @default.
• W4306173610 cites W2891214711 @default.
• W4306173610 cites W2903690341 @default.
• W4306173610 cites W2904612598 @default.
• W4306173610 cites W2912132559 @default.
• W4306173610 cites W2912707964 @default.
• W4306173610 cites W2921153272 @default.
• W4306173610 cites W2947767395 @default.
• W4306173610 cites W2962094071 @default.
• W4306173610 cites W2969709162 @default.
• W4306173610 cites W2972559932 @default.
• W4306173610 cites W2972707815 @default.
• W4306173610 cites W2982051641 @default.
• W4306173610 cites W2992804880 @default.
• W4306173610 cites W2992828409 @default.
• W4306173610 cites W2999748190 @default.
• W4306173610 cites W3001622551 @default.
• W4306173610 cites W3010907970 @default.
• W4306173610 cites W3037938661 @default.
• W4306173610 cites W3043105942 @default.
• W4306173610 cites W3084353531 @default.
• W4306173610 cites W3086537847 @default.
• W4306173610 cites W3087229737 @default.

• next